| Literature DB >> 33166616 |
Tao Jiang1, Do-Hyun Nam2, Zvi Ram3, Wai-Sang Poon4, Jiguang Wang5, Damdindorj Boldbaatar6, Ying Mao7, Wenbin Ma8, Qing Mao9, Yongping You10, Chuanlu Jiang11, Xuejun Yang12, Chunsheng Kang13, Xiaoguang Qiu14, Wenbin Li15, Shaowu Li16, Ling Chen17, Xuejun Li18, Zhixiong Liu18, Weimin Wang19, Hongmin Bai19, Yu Yao20, Shouwei Li21, Anhua Wu22, Ke Sai23, Guilin Li16, Kun Yao24, Xinting Wei25, Xianzhi Liu25, Zhiwen Zhang26, Yiwu Dai27, Shengqing Lv28, Liang Wang29, Zhixiong Lin21, Jun Dong30, Guozheng Xu31, Xiaodong Ma17, Wei Zhang32, Chuanbao Zhang15, Baoshi Chen15, Gan You15, Yongzhi Wang15, Yinyan Wang15, Zhaoshi Bao15, Pei Yang15, Xing Fan16, Xing Liu16, Zheng Zhao16, Zheng Wang15, Yiming Li15, Zhiliang Wang15, Guanzhang Li16, Shengyu Fang16, Lianwang Li16, Yanwei Liu14, Shuai Liu14, Xia Shan14, Yuqing Liu16, Ruichao Chai16, Huimin Hu16, Jing Chen16, Wei Yan33, Jinquan Cai34, Hongjun Wang34, Lingchao Chen35, Yuan Yang36, Yu Wang37, Lei Han13, Qixue Wang13.
Abstract
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.Entities:
Keywords: Chemoradiation; Immune therapy; Molecular diagnostics; Surgery; Target therapy
Mesh：
Substances：
Year: 2020 PMID： 33166616 DOI： 10.1016/j.canlet.2020.10.050
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679